Pharma deal could reduce choice and lead to higher prices for HRT treatments | Competition & Markets Authority

Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.

Related Keywords

United Kingdom ,United States ,Sorcha Ocarroll ,Theramex Viatris ,Senior Director ,Theramex ,Cma ,Hrt ,Viatris ,Uk ,Femoston ,Phase ,Duphaston ,April ,Authority ,Both ,Carroll ,Competition ,Director ,Editors ,Europe ,European ,Markets ,Mergers ,Nhs ,